Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB001
- Development stage
- Phase 2
- Lead developer
- ARTBIO
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**AB001** is ARTBIO's investigational prostate-specific membrane antigen-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer. Previously referenced as **212Pb-NG001**, it is a PSMA-binding small molecule chelated to lead-212. Following PSMA-mediated tumor localization and internalization, lead-212 and its alpha-emitting decay products deliver high-linear-energy-transfer radiation over a short path length, producing cytotoxic DNA damage in PSMA-expressing tumor cells. AB001 is being evaluated in the ARTISAN Phase 1 study, including patients who are either naïve to or previously treated with lutetium-177 PSMA radioligand therapy. ([jnm.snmjournals.org](https://jnm.snmjournals.org/content/early/2025/03/13/jnumed.124.269299))
- Other names
- [212Pb]Pb-AB001
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on AB001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB001.